Anti-Angiogenesis Strategies in Cancer Therapies
Shaker Mousa · Paul Davis
marras 2016 · Academic Press
E-kirja
210
sivuja
family_home
Kelvollinen
info
reportArvioita ja arvosteluja ei ole vahvistettu Lue lisää
Tietoa tästä e-kirjasta
Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. - Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents - Reviews FDA-approved anti-angiogenesis agents - Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents - Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Tietoja kirjoittajasta
Dr. Mousa came to Albany College of Pharmacy and Health Sciences in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. Among Dr. Mousa's professional accomplishments are his contributions to many patents – he holds more than 250 U.S. and international patents – and to the discovery and development of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial perfusion and thrombus imaging agents. Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Journal of Pharmaceutical Sciences, Frontiers in Molecular Neuroscience, Clinical and Applied Thrombosis/Hemostasis, Applied Microbiology and Biotechnology, and PLoS Computational Biology.Dr. Davis directs a group of scientists who have defined molecular mechanisms for many non-genomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. He has 5 patents issued and 25 US and international applications pending. Dr. Davis is a US Faculty Head in Endocrinology of the Faculty of 1000 Medicine and a member of the Endocrine Society, American Thyroid Association, American Society of Biochemistry and Molecular Biology, American Diabetes Association, American Association for Cancer Research and a Fellow of the American College of Physicians.
Arvioi tämä e-kirja
Kerro meille mielipiteesi.
Tietoa lukemisesta
Älypuhelimet ja tabletit
Asenna Google Play Kirjat ‑sovellus Androidille tai iPadille/iPhonelle. Se synkronoituu automaattisesti tilisi kanssa, jolloin voit lukea online- tai offline-tilassa missä tahansa oletkin.
Kannettavat ja pöytätietokoneet
Voit kuunnella Google Playsta ostettuja äänikirjoja tietokoneesi selaimella.
Lukulaitteet ja muut laitteet
Jos haluat lukea kirjoja sähköisellä lukulaitteella, esim. Kobo-lukulaitteella, sinun täytyy ladata tiedosto ja siirtää se laitteellesi. Siirrä tiedostoja tuettuihin lukulaitteisiin seuraamalla ohjekeskuksen ohjeita.
